The pharmacogenetics of methotrexate

Rheumatology

Volumn 46, Issue 10, 2007, Pages 1520-1524

  Hider, S L ^a   Bruce, Ian N ^a   Thomson, W ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

MTX; Pharmacogenetics; Rheumatoid arthritis

Indexed keywords

ADENOSINE A2 RECEPTOR; ADENOSINE MONOPHOSPHATE DEAMINASE; ARGININE; AZATHIOPRINE; DIHYDROFOLATE REDUCTASE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GAMMA GLUTAMYL HYDROLASE; HISTIDINE; METHIONINE SYNTHASE; METHIONINE SYNTHASE REDUCTASE; METHOTREXATE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); THIOPURINE METHYLTRANSFERASE; THYMIDYLATE SYNTHASE;

AMINO ACID SUBSTITUTION; DIAGNOSTIC ACCURACY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG SUBSTITUTION; ENZYME ACTIVITY; GENE AMPLIFICATION; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; LYMPHATIC LEUKEMIA; PHARMACOGENETICS; PREDICTION; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; METHOTREXATE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); THYMIDYLATE SYNTHASE; TREATMENT OUTCOME;

EID: 34848868805     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kem147     Document Type: Review

References (41)

1. Payne K, Newman W, Fargher E, Tricker K, Bruce IN, Ollier WE. TPMT testing in rheumatology: Any better than routine monitoring? Rheumatology 2007;46:727-9.
2. Pirmohamed M. Pharmacogenetics and pharmacogenomics. Br J Clin Pharmacol 2001;52:345-7.
3. Genestier L, Paillot R, Quemeneur L, Izeradjene K, Revillard JP. Mechanisms of action of methotrexate. Immunopharmacology 2000;47:247-57.
4. Hooijberg JH, Broxterman HJ, Kool M et al. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res 1999;59:2532-5.
5. Kool M, van der Linden M, de Haas M et al. MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc Natl Acad Sci U S A 1999;96:6914-9.
6. Zeng H, Chen ZS, Belinsky MG, Rea PA, Kruh GD. Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Research 2001;61:7225-32.
7. Wielinga P, Hooijberg JH, Gunnarsdottir S et al. The human multidrug resistance protein MRP5 transports folates and can mediate cellular resistance against antifolates. Cancer Res 2005;65:4425-30.
8. Chan ESL, Cronstein B.N. Molecular action of methotrexate in inflammatory diseases. Arthritis Res 2002;4:266-73.
9. Galpin AJ, Schuetz JD, Masson E et al. Differences in folylpolyglutamate synthetase and dihydrofolate reductase expression in human B-lineage versus T-lineage leukemic lymphoblasts: Mechanisms for lineage differences in methotrexate polyglutamylation and cytotoxicity. Mol Pharmacol 1997;52:155-63.
10. Banerjee D, Mayer-Kuckuk P, Capiaux G, Budak-Alpdogan T, Gorlick R, Bertino JR. Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase. Biochim Biophys Acta 2002;1587:164-73.
11. Dervieux T, Furst D, Lein DO et al. Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: Results of a multicentred cross sectional observational study. Ann Rheum Dis 2005;64:1180-5.
12. Dervieux T, Greenstein N, Kremer J. Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis. Arthritis Rheum 2006;54:3095-103.
13. Cronstein BN. The mechanism of action of methotrexate. Rheum Dis Clin North Am 1997;23:739-55.
14. Seitz M. Molecular and cellular effects of methotrexate. Current Opinion in Rheumatology 1999;11:226-32.
15. Laverdiere C, Chiasson S, Costea I, Moghrabi A, Krajinovic M. Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia. Blood 2002;100:3832-4.
16. Dervieux T, Kremer J, Lein DO et al. Contribution of common polymorphisms in reduced folate carrier and gamma-glutamylhydrolase to methotrexate polyglutamate levels in patients with rheumatoid arthritis. Pharmacogenetics 2004;14:733-9.
17. Dervieux T, Furst D, Lein DO et al. Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum 2004;50:2766-74.
18. Wessels JA, de Vries-Bouwstra JK, Heijmans BT et al. Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. Arthritis Rheum 2006;54:1087-95.
19. Ranganathan P, Culverhouse R, Marsh S et al. Single nucleotide polymorphism profiling across the methotrexate pathway in normal subjects and patients with rheumatoid arthritis. Pharmacogenomics 2004;5:559-69.
20. van der Straaten R, Wessels JA, de Vries-Bouwstra JK et al. Exploratory analysis of four polymorphisms in human GGH and FPGS genes and their effect in methotrexate-treated rheumatoid arthritis patients. Pharmacogenomics 2007;8:141-50.
21. Ranganathan P, McLeod HL. Methotrexate pharmacogenetics: The first step toward individualized therapy in rheumatoid arthritis. Arthritis Rheum 2006;54:1366-77.
22. Pullarkat ST, Stoehlmacher J, Ghaderi V et al. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics 2001;1:65-70.
23. Kumagai K, Hiyama K, Oyama T, Maeda H, Kohno N. Polymorphisms in the thymidylate synthase and methylenetetrahydrofolate reductase genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis. Int J Mol Med 2003;11:593-600.
24. Mandola MV, Stoehlmacher J, Zhang W et al. A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. Pharmacogenetics 2004;14:319-27.
25. van Ede AE, Laan RF, Blom HJ et al. The C677T mutation in the methylenetetrahydrofolate reductase gene: A genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients. Arthritis Rheum 2001;44:2525-30.
26. Schwahn B, Rozen R. Polymorphisms in the methylenetetrahydrofolate reductase gene: Clinical consequences. Am J Pharmacogen 2001;1:189-201.
27. Rozen R. Molecular genetics of methylenetetrahydrofolate reductase deficiency. J Inherit Metab Dis 1996;19:589-94.
28. Frosst P, Blom HJ, Milos R et al. A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10:111-3.
29. Ulrich CM, Robien K, Sparks R. Pharmacogenetics and folate metabolism - a promising direction. Pharmacogenomics 2002;3:299-313.
30. Weisberg I, Tran P, Christensen B, Sibani S, Rozen R. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 1998;64:169-72.
31. Van Ede AE, Laan RF, Rood MJ et al. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: A forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2001;44:1515-24.
32. Urano W, Taniguchi A, Yamanaka H et al. Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics 2002;12:183-90.
33. Hider SL, Mack LF, Shadforth MF, Thomson W, Bruce IN. Single nucleotide polymorphisms within MTHFR are associated with abnormal liver function tests in RA patients receiving MTX. Rheumatology 2006;45(Suppl. 1):i104.
34. Berkun Y, Levartovsky D, Rubinow A et al. Methotrexate related adverse effects in patients with rheumatoid arthritis are associated with the A1298C polymorphism of the MTHFR gene. Ann Rheum Dis 2004;63:1227-31.
35. Hughes LB, Beasley TM, Patel H et al. Racial or ethnic differences in allele frequencies of single-nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene and their influence on response to methotrexate in rheumatoid arthritis. Ann Rheum Dis 2006;65:1213-8.
36. Goto Y, Yue L, Yokoi A et al. A novel single-nucleotide polymorphism in the 3′-untranslated region of the human dihydrofolate reductase gene with enhanced expression. Clin Cancer Res 2001;7:1952-6.
37. Wessels JA, Kooloos WM, De Jonge R et al. Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2006;54:2830-9.
38. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005;52:3381-90.
39. Weisman MH, Furst DE, Park GS et al. Risk genotypes in folate-dependent enzymes and their association with methotrexate-related side effects in rheumatoid arthritis. Arthritis Rheum 2006;54:607-12.
40. Hider SL, Mack LF, Armstrong DJ, Shadforth MF, Bruce IN, Thomson W. Single nucleotide polymorphisms within adenosine receptor A2a are associated with gastrointestinal (GI) adverse events on MTX therapy. Rheumatology 2006;45(Suppl. 1):i104.
41. Hattersley AT, McCarthy MI. What makes a good genetic association study? Lancet 2005;366:1315-23.